Meeting
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
Authors
Toshihiko Doi
National Cancer Center Hospital East, Kashiwa, Japan
Toshihiko Doi , Noboru Yamamoto , Shigehisa Kitano , Robert Latek , Jianrui Hou , Yuko Tanaka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT06091930
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS2669)
DOI
10.1200/JCO.2024.42.16_suppl.TPS2669
Abstract #
TPS2669
Poster Bd #
148a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
First Author: Gustav J. Ullenhag
Poster
2020 ASCO Virtual Scientific Program
SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.
First Author: Amita Patnaik
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
First Author: Aparna Raj Parikh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska